Silo Pharma, Inc. — Investor Relations & Filings
Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on developing novel therapeutics for underserved medical conditions by merging traditional pharmaceuticals with psychedelic research. The company's portfolio targets a range of indications, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Key development programs include SPC-15 for post-traumatic stress disorder (PTSD) and SP-26 for fibromyalgia, alongside preclinical assets for Alzheimer's disease and multiple sclerosis. Silo Pharma utilizes the 505(b)(2) regulatory pathway for certain licensed therapeutics to potentially streamline the approval process. The company conducts its research through collaborations with universities and laboratories to build its intellectual property portfolio.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| QUARTERLY REPORT | 2026-05-13 | English | |
| 424B3 - Silo Pharma, Inc. (0001514183) (Filer) | 2026-04-16 | English | |
| 424B3 - Silo Pharma, Inc. (0001514183) (Filer) | 2026-04-14 | English | |
| 10-K - Silo Pharma, Inc. (0001514183) (Filer) | 2026-03-27 | English | |
| 8-K - SILO PHARMA, INC. (0001514183) (Filer) | 2026-02-23 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 45938822 | QUARTERLY REPORT | 2026-05-13 | English | ||
| 34649948 | 424B3 - Silo Pharma, Inc. (0001514183) (Filer) | 2026-04-16 | English | ||
| 34526957 | 424B3 - Silo Pharma, Inc. (0001514183) (Filer) | 2026-04-14 | English | ||
| 33065917 | 10-K - Silo Pharma, Inc. (0001514183) (Filer) | 2026-03-27 | English | ||
| 32892992 | 8-K - SILO PHARMA, INC. (0001514183) (Filer) | 2026-02-23 | English | ||
| 30259414 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30259413 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
|
2025
8 filings
| |||||
| 12428752 | CURRENT REPORT | 2025-12-29 | English | ||
| 12428748 | Director's Dealing 2025 | 2025-12-17 | English | ||
| 12428754 | Regulatory Filings 2025 | 2025-11-28 | English | ||
| 12428755 | PROSPECTUS | 2025-11-26 | English | ||
| 12428749 | Director's Dealing 2025 | 2025-11-22 | English | ||
| 12428751 | Director's Dealing 2025 | 2025-11-20 | English | ||
| 12428757 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 12428760 | QUARTERLY REPORT | 2025-11-13 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
ANHUI FENGYUAN PHARMACEUTICAL CO., LTD
Produces injections, solid dosage forms, APIs, and nutritio…
|
000153 | CN | Manufacturing |
|
Anhui Huangshan Capsule Co.,Ltd
Produces empty hard capsules, including gelatin and HPMC ve…
|
002817 | CN | Manufacturing |
|
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
Develops and manufactures pharmaceutical excipients for sol…
|
300452 | CN | Manufacturing |
|
Anika Therapeutics, Inc.
A global joint preservation company developing solutions fo…
|
ANIK | US | Manufacturing |
|
ANIMALCARE GROUP PLC
Develops and commercializes veterinary pharmaceutical produ…
|
ANCR | GB | Manufacturing |
|
ANI PHARMACEUTICALS INC
Develops, manufactures, and markets branded, generic, and O…
|
ANIP | US | Manufacturing |
|
ANLON HEALTHCARE LIMITED
Researches and manufactures APIs, intermediates, and finish…
|
AHCL | IN | Manufacturing |
|
Annexin Pharmaceuticals AB
Clinical-stage biotech developing a cell-protecting biologi…
|
ANNX | SE | Manufacturing |
|
Annexon, Inc.
Clinical-stage biopharma developing complement medicines by…
|
ANNX | US | Manufacturing |
|
Antengene Corporation Limited
Global biopharma developing and commercializing novel oncol…
|
6996 | KY | Manufacturing |
Silo Pharma, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35304/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35304 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35304 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35304 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35304}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Silo Pharma, Inc. (id: 35304)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.